NMT Medical, AGA Medical settle
This article was originally published in The Gray Sheet
In return for full and final settlement of NMT's 1999 patent infringement suit, AGA will pay NMT $30 mil. for a nonexclusive sublicense to patent '420, which relates to NMT's CardioSeal, the two firms announced March 28. The alleged infringement affects all AGA Amplatzer occluding devices. NMT will split the settlement with inventor Lloyd Marks, MD, according to the firm. NMT competes with AGA in the patent foramen ovale occlusion market with STARFlex. Preliminary results of NMT's MIST I trial suggest a connection between patent foramen ovale closure and migraine symptoms (1"The Gray Sheet" March 20, 2006, p. 3)...
You may also be interested in...
Preliminary clinical trial data show NMT Medical's STARflex patent foramen ovale (PFO) closure device to be no more effective than placebo in completely eliminating migraine headaches, although the device did appear to improve some symptoms
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.
AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.
Payers would welcome any additional clarity provided by advisory panel review, given the perception, expressed in a recent ICER report, that the evidence is insufficient to determine whether the new drug is safer or more effective than erythropoiesis-stimulating agents.